Subclinical Hypothyroidism with Negative for Thyroid Peroxidase Antibodies in Pregnancy: Intellectual Development of Offspring

Thyroid ◽  
2021 ◽  
Author(s):  
Jiajia Chen ◽  
Jing Zhu ◽  
Xianping Huang ◽  
Shenzhi Zhao ◽  
Huiqiu Xiang ◽  
...  
Keyword(s):  
Subclinical Hypothyroidism ◽  
Intellectual Development ◽  
Thyroid Peroxidase ◽  
Thyroid Peroxidase Antibodies ◽  
In Pregnancy

Subclinical hypothyroidism

2019 ◽  
Vol 12 (3) ◽  
pp. 131-135
Author(s):  
Adam Grice
Keyword(s):  
Cardiovascular Disease ◽  
Subclinical Hypothyroidism ◽  
Thyroid Stimulating Hormone ◽  
Normal Serum ◽  
Overt Hypothyroidism ◽  
Thyroid Peroxidase ◽  
Autoimmune Thyroid ◽  
Thyroid Peroxidase Antibodies ◽  
Increased Risk ◽  
Stimulating Hormone

Subclinical hypothyroidism is a common condition associated with a raised thyroid-stimulating hormone and a normal serum free thyroxine that affects about 10% of females over 55 years in age. The most common cause is autoimmune thyroid disease, with 2.5% of patients with subclinical hypothyroidism progressing to clinically overt hypothyroidism each year. The rate of progression is higher in patients with anti-thyroid peroxidase antibodies and higher levels of thyroid-stimulating hormone. Only a small proportion of patients with subclinical hypothyroidism have symptoms, and although there is some debate in the literature about which patients should be treated, the National Institute for Health and Care Excellence clinical knowledge summaries give clear recommendations. There is an increased risk of cardiovascular disease in patients with subclinical hypothyroidism; it is uncertain whether treatment with levothyroxine reduces this risk. When deciding whether to treat subclinical hypothyroidism consider the patient’s age, symptoms, presence of anti-thyroid peroxidase antibodies, thyroid-stimulating hormone levels and risk factors such as cardiovascular disease.

scholarly journals Subclinical Hypothyroidism in Pregnancy: Intellectual Development of Offspring

Thyroid ◽  
2011 ◽  
Vol 21 (10) ◽  
pp. 1143-1147 ◽  
Author(s):  
Hossein Ghorbani Behrooz ◽  
Maryam Tohidi ◽  
Yadollah Mehrabi ◽  
Ebrahim Ghorbani Behrooz ◽  
Mehdi Tehranidoost ◽  
...  
Keyword(s):  
Subclinical Hypothyroidism ◽  
Intellectual Development ◽  
In Pregnancy

scholarly journals Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy

2009 ◽  
Vol 94 (11) ◽  
pp. 4608-4612 ◽  
Author(s):  
Beverley M. Shields ◽  
Rachel M. Freathy ◽  
Bridget A. Knight ◽  
Anita Hill ◽  
Michael N. Weedon ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Subclinical Hypothyroidism ◽  
Reference Range ◽  
Adverse Outcomes ◽  
Thyroid Peroxidase ◽  
Intention To Treat ◽  
Recommended Treatment ◽  
Normal Ranges ◽  
Serum Tsh ◽  
In Pregnancy

Background: Maternal subclinical hypothyroidism is associated with a number of adverse outcomes in pregnancy. The Endocrine Society’s recent consensus guidelines have recommended treatment with T4 for this condition in pregnancy. The single nucleotide polymorphism rs4704397 in the phosphodiesterase 8B (PDE8B) gene has been found to be associated with altered serum TSH concentrations in the general population. We aimed to assess whether genetic variation in TSH due to the rs4704397 genotype affects the number of individuals classified as having subclinical hypothyroidism in pregnancy. Methods: Serum TSH, FT4, FT3, and thyroid peroxidase antibodies (TPOAbs) were measured in 970 pregnant women at 28 wk gestation. rs4704397 genotype was available on 877 subjects. Reference range calculations were based on the TPOAb-negative women. Results: TSH, but not FT4, FT3, or TPOAbs, varied with genotype and was highest in those with the AA genotype (median, 2.16, 1.84, and 1.73 mIU/liter for AA, AG, and GG genotypes, respectively; P = 0.0004). A greater proportion of women with the AA genotype had TSH concentrations above 4.21 mIU/liter, the upper limit of the reference range, compared with the AG and GG genotypes (9.6 vs. 3.5%, respectively; P = 0.004). Maternal PDE8B genotype was not associated with offspring birthweight or gestational age at delivery. Conclusion: Genetic variation in TSH levels in pregnancy associated with the PDE8B rs4704397 genotype has implications for the number of women treated for subclinical hypothyroidism under current guidelines. Consideration should be made to individualization of normal ranges, potential effects on pregnancy outcome, and intention to treat for subclinical hypothyroidism in pregnancy. Variation in the PDE8B gene leads to alteration in serum TSH concentration and different proportions of women picked up with subclinical hypothyroidism in pregnancy.

scholarly journals Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy

Endocrinology ◽  
2009 ◽  
Vol 150 (11) ◽  
pp. 5191-5191
Author(s):  
Beverley M. Shields ◽  
Rachel M. Freathy ◽  
Bridget A. Knight ◽  
Anita Hill ◽  
Michael N. Weedon ◽  
...  
Keyword(s):  
Genetic Variation ◽  
Subclinical Hypothyroidism ◽  
Reference Range ◽  
Adverse Outcomes ◽  
Thyroid Peroxidase ◽  
Intention To Treat ◽  
Recommended Treatment ◽  
Normal Ranges ◽  
Serum Tsh ◽  
In Pregnancy

ABSTRACT Background: Maternal subclinical hypothyroidism is associated with a number of adverse outcomes in pregnancy. The Endocrine Society’s recent consensus guidelines have recommended treatment with T4 for this condition in pregnancy. The single nucleotide polymorphism rs4704397 in the phosphodiesterase 8B (PDE8B) gene has been found to be associated with altered serum TSH concentrations in the general population. We aimed to assess whether genetic variation in TSH due to the rs4704397 genotype affects the number of individuals classified as having subclinical hypothyroidism in pregnancy. Methods: Serum TSH, FT4, FT3, and thyroid peroxidase antibodies (TPOAbs) were measured in 970 pregnant women at 28 wk gestation. rs4704397 genotype was available on 877 subjects. Reference range calculations were based on the TPOAb-negative women. Results: TSH, but not FT4, FT3, or TPOAbs, varied with genotype and was highest in those with the AA genotype (median, 2.16, 1.84, and 1.73 mIU/liter for AA, AG, and GG genotypes, respectively; P = 0.0004). A greater proportion of women with the AA genotype had TSH concentrations above 4.21 mIU/liter, the upper limit of the reference range, compared with the AG and GG genotypes (9.6 vs. 3.5%, respectively; P = 0.004). Maternal PDE8B genotype was not associated with offspring birthweight or gestational age at delivery. Conclusion: Genetic variation in TSH levels in pregnancy associated with the PDE8B rs4704397 genotype has implications for the number of women treated for subclinical hypothyroidism under current guidelines. Consideration should be made to individualization of normal ranges, potential effects on pregnancy outcome, and intention to treat for subclinical hypothyroidism in pregnancy.

Sign in / Sign up

Export Citation Format

Share Document